The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/&beta;-Catenin pathway | Zendy

Linwei Jia | Zendy; Yaohui Tian | Zendy; Yonghan Chen | Zendy; Gang Zhang | Zendy

Open Access

The silencing of LncRNA-H19 decreases chemoresistance of human glioma cells to temozolomide by suppressing epithelial-mesenchymal transition via the Wnt/β-Catenin pathway

Author(s) -

Linwei Jia,

Yaohui Tian,

Yonghan Chen,

Gang Zhang

Publication year - 2018

Publication title -

oncotargets and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.054

H-Index - 60

ISSN - 1178-6930

DOI - 10.2147/ott.s154339

Subject(s) - temozolomide , glioma , small hairpin rna , cancer research , gene silencing , gene knockdown , epithelial–mesenchymal transition , wnt signaling pathway , survivin , u87 , apoptosis , chemistry , medicine , cancer , signal transduction , metastasis , biochemistry , gene

Temozolomide (TMZ) is commonly used for glioma chemotherapy. However, TMZ resistance limits the therapeutic effect of TMZ in glioma treatment. LncRNA-H19 acts as an oncogenic LncRNA in some types of cancers and has been reported to be up-regulated in glioma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research